PARKINSON KASALLIGI VA IKKILAMCHI PARKINSONIZMNING KLINIK KECHISH XUSUSIYATLARI (adabiy sharh)
##article.subject##:
Parkinson kasalligi, ikkilamchi parkinsonizm, qon-tomir (vaskulyar) parkinsonizmi, atipik parkinsonizm, klinik belgilar, differensial diagnostika, patogenez, neyrodegenerativ kasalliklar##article.abstract##
Parkinson kasalligi (PK) — keng tarqalgan neyrodegenerativ kasallik bo‘lib, surunkali rivojlanish xususiyatiga ega va harakat bilan bog‘liq (motor) hamda harakat bilan bog‘liq bo‘lmagan (nomotor) simptomlar bilan kechadi. Ikkilamchi parkinsonizm esa ma’lum etiologiyali boshqa kasalliklarning asorati hisoblanadi (miya qon-tomir zararlanishi, bosh miya jarohatlari, o‘smalar, gidrosefaliya, dori vositalari bilan davolash yoki toksik omillar ta’siri). Ushbu patologik holatlarni klinik jihatdan farqlashni bilish aniq tashxis qo‘yish va optimal davolash taktikasini tanlashda muhim ahamiyatga ega. Mazkur tahliliy maqolaning maqsadi - parkinsonizm sindromi bilan namoyon bo‘ladigan holatlarning, jumladan, qon-tomir, dori vositalariga bog‘liq va atipik parkinsonizmlarning patogenezi va klinik belgilari haqidagi zamonaviy qarashlarni qiyosiy tizimlashtirishdan iborat.
Библиографические ссылки
Гашилова Ф.Ф. Клинические и параклинические аспекты паркинсонизма в Томске. Автореферат дис... канд. мед. наук. Новосибирск, 2016.
заболеваниях. Диагностика и лечение экстрапирамидных расстройств. Под ред. В.Н. Штока., И.А. Ивановой-Смоленской, О.С. Левина. М.: Медпресс-информ, 2003. с.503–519.
Левин О.С. Сосудистый паркинсонизм: 20 лет спустя. РМЖ 2020; №21: с.1500-1506.
Левин О.С. Экстрапирамидные синдромы при цереброваскулярных заболеваниях. Диагностика и лечение экстрапирамидных расстройств. Под ред. В.Н. Штока., И.А. Ивановой-Смоленской, О.С. Левина. М.: Медпресс-информ, 2003. с.503–519.
Baldereschi M., Di Carlo A., Vanni P., et al. Italian Longitudinal Study on Aging Working Group. Lifestyle-related risk factors for Parkinson's disease: a population-based study. Ada Neurol Scand 2003; №108: 10: 239-244.
Benito–León J., Bermejo-Pareja F., Morales-Gonzalez J.M. et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004; 734-741.
Blauwendraat C., Nalls M.A., Singleton A. B. The genetic architecture of Parkinson's disease. Lancet Neurology 2020; №19(2):170-178.
Coon E.A., Singer W. Synucleinopathies. Continuum 2020; №26(1):72-92.
Factor S. A., Weiner W.J. Parkinson's Disease. Diagnosis and Clinical Management. 2008; 819.
Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol .Neurosurg. Psychiatry 2022; № 51 (6): 745-752.
Hirtz D., Thurman D.J., Gwinn-Hardy K., et al. How common are the "common" neurologic disorders? Neurology 2017; № 68: 326-337.
Höllerhage M. Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults. Neurobiol 2019; №149:377-418.
Jellinger K.A. Vascular parkinsonism. Therapy 2008; № 5(2): 237–255.
Kovacs G.G. Tauopathies. Clin Neurol 2017; №145: 355-368.
Lang A.E. Corticobasal degeneration: selected developments. Mov Disord 2013; №18 (6): 51-56.
McKeith I.G., Boeve B.F., Dickson D.W. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; №89: c. 1–13.
Saiki S., Sato S., Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 2015; №83 (4): 430–436.
Schapira A. H., Jenner J. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2018; №26(6):1049-55.
Terashi H., Taguchi T., Aizawa H. Secondary parkinsonism. Nihon Rinsho 2017; №75 (1): 63-70.
Twelves D., Perkins K.S., Counsell С. Systematic review of incidence studies of Parkinson's disease. MovDisord 2003; №18 (1): 19-31.
Van Den Eeden S.K., Tanner C.M., Bernstein A.L. et al. lncidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol 2003; №157: 1015-1022.
Wirdefeldt K., Adami H.O., Cole P., et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; №26(1): 1-58.
